节点文献

贵州省1952-2024年流行性脑脊髓膜炎流行病学特征和脑膜炎奈瑟菌血清群变迁趋势

Epidemiology of meningococcal meningitis and serogroup changes of Neisseria meningitidis in Guizhou province, 1952-2024

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杨利; 刘淳婷; 芮莉萍; 张亚琴; 赵玲璐; 余小娅; 李军; 刘铭;

【Author】 Yang Li;Liu Chunting;Rui Liping;Zhang Yaqin;Zhao Linglu;Yu Xiaoya;Li Jun;Liu Ming;School of Public Health and Health Management, Guizhou Medical University, Key Laboratory of Environmental Pollution and Disease Monitoring;Guizhou Provincial Center for Disease Control and Prevention;

【通讯作者】 刘铭;

【机构】 贵州医科大学公共卫生与健康学院,环境污染与疾病监控教育部重点实验室; 贵州省疾病预防控制中心;

【摘要】 目的 分析贵州省流行性脑脊髓膜炎(流脑)流行特征和脑膜炎奈瑟菌(Neisseria meningitidis, Nm)血清群变迁趋势。方法 收集贵州省1952-2024年流脑报告病例流行病学和Nm血清群监测信息,分析流脑报告发病率和Nm血清群构成;采用中断时间序列分析评价脑膜炎球菌疫苗纳入贵州省免疫规划(Expanded Program on Immunization, EPI)前后发病率变化。结果 贵州省1952-2024年共报告流脑175 575例,年均报告发病率(/10万,下同)为8.345,各年报告发病率在0.003(2016年和2017年)~220.410(1967年)之间。在2000-2024年报告病例中,0~4岁、5~9岁、10~14岁、15~19岁、≥20岁年均报告发病率分别为0.847、0.798、0.529、0.200、0.036。中断时间序列分析显示,脑膜炎球菌疫苗纳入EPI前期(1994-2005年)、纳入EPI时期(2007-2024年)流脑发病率均呈下降趋势[β(95%CI):-0.101(-0.138~-0.063)、-0.014(-0.028~-0.002)]。在2007-2024年报告病例中,Nm血清群检测阳性57例,其中A群19例(2008-2013年)、B群21例(2016年、2018-2024年)、C群13例(2007-2008年、2013年、2019年、2021-2022年、2024年)、Y群4例(2023-2024年)。结论 贵州省1952-2024年流脑发病总体呈下降趋势,发病以<15岁儿童为主,优势Nm血清群从A群变迁为B群、C群和Y群,脑膜炎球菌疫苗纳入EPI后使流脑发病率进一步下降。建议持续开展Nm血清群监测,加强适龄儿童脑膜炎球菌疫苗常规免疫工作。

【Abstract】 Objective To determine epidemiological characteristics of meningococcal meningitis(MM) and changes of Neisseria meningitidis(Nm) serogroups in Guizhou province.Methods We obtained epidemiological and serogroup data on MM cases reported during 1952-2024 in Guizhou to determine MM incidence and serogroup distribution. We used interrupted time series analysis to evaluate changes in MM incidence before and after introducing meningococcal vaccine into Guizhou′s Expanded Program on Immunization(EPI).Results During 1952-2024, there were 175 575 MM cases reported in Guizhou, for an average annual incidence of 8.345 per 100 000 population. Incidences per 100 000 by year ranged from 0.003 in 2016 and 2017 to 220.410 in 1967. In 2000-2024, average annual incidences for 0-4-, 5-9-, 10-14-, 15-19-, and ≥20-year-olds were 0.847, 0.798, 0.529, 0.200, and 0.036 per 100 000, respectively. Interrupted time series analysis showed that MM incidences in the pre-EPI period(1994-2005) and the EPI period(2007-2024) both declined [β(95% CI):-0.101(-0.138 to-0.063) and-0.014(-0.028 to-0.002)]. Fifty-seven MM cases reported during 2007-2024 were positive to an Nm serogroup, including 19 serogroup A cases(in 2008-2013), 21 serogroup B cases(in 2016 and 2018-2024), 13 serogroup C cases(in 2007-2008, 2013, 2019, 2021-2022, and 2024), and 4 serogroup Y cases(in 2023-2024).Conclusions MM incidence decreased during 1952-2024 in Guizhou; most cases were in children under 15 years of age. The predominant Nm serogroup shifted from serogroup A to serogroups B, C, and Y. MM incidence decreased further after introduction of meningococcal vaccine into EPI. We suggest continuous monitoring of Nm serogroups and strengthening routine meningococcal vaccination for age-eligible children.

【基金】 贵州省科技计划项目(黔科合基础-ZK[2024]一般617)
  • 【文献出处】 中国疫苗和免疫 ,Chinese Journal of Vaccines and Immunization , 编辑部邮箱 ,2025年03期
  • 【分类号】R181.3;R515.2
  • 【下载频次】60
节点文献中: 

本文链接的文献网络图示:

本文的引文网络